Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation for IBI351 for the treatment of previously treated advanced colorectal carcinoma patients with KRASG12C mutation.
